Liquid Dosage

Monoclonal Antibodies

GEA is a leading specialist in the field of process equipment for liquid processing and metering for the pharmaceutical and biotech industries, including fermentation plant for the manufacture of products such as monoclonal antibodies (mAbs) for diagnostic and therapeutic purposes.

Monoclonal antibodies are known as targeted therapies because they work by targeting specific proteins on the surface of cells. Successfully used to treat cancers, tumors and other serious diseases, mAbs are — compared with other biopharmaceutical products — large proteins that require relatively high administration doses and traditionally necessitate high-volume manufacturing equipment/systems and facilities. GEA offers production systems for monoclonal antibodies that are produced in state-of-the-art stainless steel bioreactors by specific cell cultures.

From Culture to Harvest

The cell culture process is done in several steps, starting with 10 L precultures and successively cultivating intermediate batches up to a final production volume of up to 20,000 L. These systems comprise the vessel, with the stirrer as the core element, and peripherals such as temperature control systems, clean-in-place (CIP) components, aeration and deaeration systems, input systems and automated sensors, actuators and the operator interface. 

Support processes, such as media preparation and harvest systems are also available from GEA. The process integration of separators and filters for the harvest step is also within GEA’s scope of service. Because of the high sensitivity of the cells and the need for operator and product safety, all GEA system components are designed according to the latest standards and have the highest grade of finish quality.

GEAインサイト

食卓に登場するニューフードが食の未来を創造

コーヒー、カカオ、牛乳、肉、魚、卵。こういった毎日の定番ともいえる食材は、集約農業に大きく依存しています。ニューフード技術の台頭に伴い、これまで以上に持続可能な代替食品を使用できるようになりました。そこで今回は、GEA で液体・発酵・充填担当上級副社長を務めるライマー・グッテ博士と対談し、その可能性と政策について探ってみました。

Innovating patient care with aseptic spray drying

At GEA, our commitment to engineering for a better world fuels our pursuit of innovative solutions that enhance patient care and safety. One of our most promising ventures in recent years is aseptic spray drying – a technology...

レシチンが単なる副産物から主役に変貌を遂げるまで

GEA製品販売部長のパトリック・シュールマンにとって、レシチンは特別な存在です。当初は食用油の精製において脇役にすぎなかったものの、何にでも使える物質として、競争が激しく利益率の低い食用油精製市場で見事に主役の座を獲得。実はこれ、シュールマンが同僚と一緒に開発した、革新的で省エネな新製法によるところが大きいのです。

GEAの最新情報をお届け

GEAからのニュース配信にサインアップして頂ければ、GEAのイノベーションやストーリーの最新情報を受け取ることができます。

連絡先

ご要望をお伺いいたします。ご要望の詳細をご入力いただければ、お問い合わせに回答いたします。